Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-800-25 botensilimab ± balstilimab vs standard of care in refractory metastatic colorectal cancer
2022-502065-23-00Phase 2Authorised
- Sponsor
- Agenus Inc.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of botensilimab in colorectal cancer (CRC) (5 arms), sponsored by Agenus Inc. Primary endpoint: Objective Response Rate. Planned start Mar 2023; status: authorised.
02
Drugs
botensilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-502065-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502065-23-00.